- Illumina (NASDAQ:ILMN) and privately held FlowJo, LLC ink a partnership to develop and co-promote analysis software for single cell next-generation sequencing (NGS) data. The application, to be developed by FlowJo, will provide additional secondary and tertiary analysis and visualization of datasets related to single cell phenotyping.
- The software, expected to be available in Q1 2017, will complement the end-to-end commercial solution for high throughput sequencing of single cells that Illumina is co-developing with Bio-Rad (BIO).